JNJ-70033093 + digoxin

JNJ-70033093 + digoxin is a **combination** of two drugs: JNJ-70033093 (also called milvexian or BMS-986177) and digoxin. JNJ-70033093 is a highly selective, oral, direct small molecule inhibitor of **factor XIa** (FXIa), under development as an anticoagulant intended to prevent and treat thrombotic events without significantly increasing the risk of bleeding. It is being developed by Bristol-Myers Squibb and Janssen Research & Development. Digoxin is a well-established **cardiac glycoside** used to treat heart failure and arrhythmias by inhibiting the sodium-potassium ATPase, thus increasing cardiac contractility. This combination is not a branded or formally approved co-formulation, but is a notional combination that may be studied in clinical pharmacology to assess interactions or co-prescribing in specific patient populations.